Therapies for inter-relating diabetes and obesity – GLP-1 and obesity

Iepsen, Eva Winning; Torekov, Signe S.; Holst, Jens J.

doi:10.1517/14656566.2014.965678

Cited by 38 publications

(34 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One pharmacological strategy involves targeting the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is a gut derived hormone released from L cells after food intake and exhibits pleiotropic effects throughout the body, including physiological regulation of appetite and calorie intake; GLP-1 levels are reduced in obese patients [11][12][13][14].…”

Section: Liraglutide In Obesity: a Summarymentioning

confidence: 99%

“…GLP-1 may act indirectly via stimulation of intestinal vagal afferents, with subsequent actions at satiation centres in the CNS, but also may act directly by entering the brain via the circumventrilcular organs (a region where peptides from the peripheral circulation are not blocked by the blood-brain barrier) to activate CNS nuclei involved in satiation [11][12][13][14][15]. Evidence from animal studies suggests that weight lowering effects of liraglutide are primarily mediated through central effects, specifically via GLP-1 receptors on arcuate nucleus neurons expressing propiomelanocortin (POMC)/cocaineand amphetamine-regulated transcript (CART) [16].…”

Section: Liraglutide In Obesity: a Summarymentioning

confidence: 99%

“…Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenyl cyclase activation via the stimulatory G-protein Gs [11][12][13][14]. GLP-1 receptors are widely distributed throughout the body, including in the pancreas, stomach, intestine, lung, kidney, heart, peripheral nervous system and CNS [19].…”

Section: Pharmacodynamic Propertiesmentioning

confidence: 99%

“…GLP-1 receptors are widely distributed throughout the body, including in the pancreas, stomach, intestine, lung, kidney, heart, peripheral nervous system and CNS [19]. Activation of GLP-1 receptors triggers several responses, including glucose-dependent stimulation of pancreatic insulin secretion and inhibition of pancreatic glucagon secretion (glucoregulatory effects) and regulation of appetite and calorie intake [11][12][13][14]. This section focuses on the effects of liraglutide in reducing bodyweight.…”

Section: Pharmacodynamic Propertiesmentioning

confidence: 99%

See 3 more Smart Citations

Liraglutide: A Review of Its Use in the Management of Obesity

Scott

2015

Drugs

View full text Add to dashboard Cite

Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer perspective. Although lifestyle interventions are fundamental in its management, in the real world setting most obese or overweight adults require adjunctive pharmacotherapy to achieve clinically relevant reductions in bodyweight (i.e. a ≥5 % reduction). Subcutaneous liraglutide (Saxenda(®)) 3 mg once daily is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic bodyweight management in adults with an initial body mass index (BMI) of ≥30 kg/m(2) (obese) or a BMI of ≥27 kg/m(2) (overweight) and at least one bodyweight-related comorbidity [e.g. hypertension, dyslipidaemia, type 2 diabetes mellitus or obstructive sleep apnoea (OSA)]. In phase III trials (32 or 56 weeks' duration) in these populations, subcutaneous liraglutide was associated with clinically relevant reductions in fasting bodyweight and was generally well tolerated. Liraglutide was significantly more effective than placebo in terms of reductions in fasting bodyweight and waist circumference, and improvements in some biomarkers of cardiovascular risk. Improvements in bodyweight were maintained after up 2 years of liraglutide therapy. In nondiabetic adults with moderate to severe OSA, liraglutide improved apnoea-hypopnoea index scores at 32 weeks, which was largely driven by significant reductions in bodyweight. In the absence of head-to-head trials, the relative position of individual anti-obesity drugs remains to be fully determined. In the meantime, liraglutide is an emerging option, as an adjunct to a reduced-calorie diet and increased physical activity, for chronic bodyweight management in obese adults and overweight adults with at least one bodyweight-related comorbidity.

show abstract

Section: Liraglutide In Obesity: a Summarymentioning

confidence: 99%

Section: Liraglutide In Obesity: a Summarymentioning

confidence: 99%

Section: Pharmacodynamic Propertiesmentioning

confidence: 99%

Section: Pharmacodynamic Propertiesmentioning

confidence: 99%

See 2 more Smart Citations

Liraglutide: A Review of Its Use in the Management of Obesity

Scott

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…However, it is unclear whether peripherally released GLP-1 needs to enter the brain to affect food intake, or whether other routes of action are involved on feeding behavior [19]. Therefore, weight loss seems to be resulting from combined central and peripheral actions of GLP-1 receptor agonists, collectively promoting satiety, decreasing hunger sensation and ultimately leading to reductions in food intake [19,51].…”

Section: Glp-1 Receptor Agonistsmentioning

confidence: 99%